Pharmaceutical Chemistry Faculty
Professor Cory Berkland earned a BS in chemical engineering at Iowa State University, an MS in chemical engineering from the University of Illinois and a PhD in chemical and bimolecular engineering at the University of Illinios. He also completed his post doc work at the University of Illinois.
Distinguished Professor Borchardt's research interests include peptide transport, prodrugs of peptides, blood-brain barrier, intestinal mucosal barrier, cell culture systems, protein and peptide stability.
Professor Brandon DeKosky earned a B.S. in Chemical Engineering from the University of Kansas in 2010 and a Ph.D. in Biochemical Engineering from the University of Texas at Austin in 2015. He completed a Post Doc in Immunology & Vaccinology at the Vaccine Research Center, National Institute of Allergy and Infectious Diseases in Bethesda, MD in 2017.
Associate Professor Laird Forrest earned a BS in chemical engineering from Auburn University and an MS in chemical engineering at the University of Illinois-Urbana. He also earned a PhD in chemical and biomolecular engineering at the University of Illinois-Urbana. He completed a postdoctoral fellowship in pharmaceutical sciences at the University of Wisconsin.
Professor Hageman earned his B.S. in Pharmacy and Ph.D. in Pharmaceutical Chemistry from the University of Kansas. His research experiences have included industrial positions in R&D at Pharmacia, Pfizer and Bristol-Myers Squibb. See more detail below.
Ph.D., Pharmaceutical Chemistry, University of Kansas
M.S., Pharmaceutical Chemistry, University of Kansas
B.S., Pharmacy, University of Kansas
1985-1987 Scientist I, Pharmacy Research, Veterinary Biologics, Upjohn Co., Kalamazoo, MI
1987-1990 Scientist II, Drug Delivery R&D, Human and Veterinary, Upjohn Co., Kalamazoo, MI
1991-1996 Senior Research Scientist III, Solubilized Formulation Design, Upjohn Co., Kalamazoo, MI
1996-1999 Senior Scientist/Group Leader, Exploratory Formulations, Pharmacia & Upjohn, Kalamazoo, MI
1999-2003 Senior Fellow/Group Leader, Global Pharmaceutical Sciences Exploratory Formulations, Pharmacia Co., Kalamazoo, MI
2002-2004 Head Global Workstream for Cross-division Re-engineering of Biological Target Selection to First in Human Process, Pharmacia Co., Kalamazoo, MI
2003-2005 Sr. Res. Fellow/Group Leader, Exploratory Formulations, Pfizer Global R&D, Kalamazoo, MI
2004-2005 Chair of Michigan Cross-Divisional Pharmaceutical Sciences Technology Group, Pfizer Global R&D, Kalamazoo & Ann Arbor, MI
2005-2013 Group Director, Discovery Pharmaceutics, Bristol-Myers Squibb, Princeton, NJ
2007-2010 Pharmaceutical Candidate Optimization Site Lead, Bristol-Myers Squibb, Princeton, NJ
2012-2016 Global Matrix Team Head, Biochemical & Biophysical Characterization
Network for Biologics, Bristol-Myers Squibb, Princeton, NJ
2013-2016 Executive Director, Pharmaceutical Candidate Optimization, Discovery Pharmaceutics, Bristol-Myers Squibb, Princeton, NJ
2017-present Valentino J. Stella Distinguished Professor, Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS
Summary of Scientific Experiences
Prior to joining the Department of Pharmaceutical Chemistry at The University of Kansas as a Distinguished Professor in 2017, I spent 30+ years working in the Pharmaceutical Industry. I have extensive experience in physicochemical characterization and preclinical assessment of new chemical entities (NCE), including proteins, peptides, oligonucleotides, protein drug conjugates, prodrugs, and other small molecule based therapeutics. I have been directly involved in the Discovery process with chemical lead selection, chemical lead optimization, and drug candidate selection for transition into clinical development. Those preclinical experiences include drug delivery research for both parenteral and oral dosage form design, with particular emphasis on designing specialized formulation strategies to overcome poor drug stability and poor aqueous solubility, with the ultimate goal of enhancing developability and commercialization. I have extensive experience, and resulting patents, on the generation of solublilzed dosage forms for administration, parenteral and oral, of both immediate release and controlled release dosage forms. Similarly, critical experience in factors which influence processing technologies, such as lyophilization and spray drying for both biologics and small molecule NCE, provides a window to later phase manufacturing challenges. In depth lab work utilizes a materials characterization approach to understand the fundamental role of both physicochemical and physicomechanical properties in both the chemical and physical stability within these amorphous systems, which dictate the resulting bioperformance of these systems. I have expertise at understanding the role of polymers and excipients in both the dissolution behaviour of these solid dispersion systems and their ability to produce and maintain supersaturated drug concentrations to enhance oral absorption. My background in industrial R&D, my experience in physical analysis, formulation screening, and developability assessment of numerous different drug modalities, will all provide me the background necessary to support the practical delivery aspects of this project in a way which has a line-of-sight to clinical evaluation and a potential product..
Dr. Jeff Krise is currently an associate professor of pharmaceutical chemistry at the University of Kansas. He holds a Bachelor of Science degree in pharmacy from Duquesne University (1993). He earned his PhD (with honors) from the Department of Pharmaceutical Chemistry at the University of Kansas in 1998. Dr. Krise completed one year of his PhD training at the Victorian College of Pharmacy (now Monash University) in Melbourne, Australia. Dr. Krise received postdoctoral training at Stanford University School of Medicine from 1998 to 2001 in the Department of Biochemistry. In 2001 he began his academic career at the University of North Carolina at Chapel Hill in the Division of Drug Delivery and Disposition. In 2004 he moved to back to the University of Kansas in the Department of Pharmaceutical Chemistry.
Distinguished Professor C. Russell Middaugh earned a B.S. from the University of California, Santa Cruz, a Ph.D. from Cornell University and completed his postdoctoral fellowship at the University of Minnesota.
Professor Picking earned her Ph.D. at the University of Kansas. Her research interests are vaccine development - especially for the children of low income countries, Enteric bacterial pathogens, and type III secretion.
Many Gram-negative bacterial pathogens possess a type III secretion system that is responsible for injecting proteins into a host cell to subvert normal host cell processes for the benefit of the pathogen – often to promote invasion of the cell. The injection nanomachine is called the type III secretion apparatus (T3SA) and it resembles a syringe embedded in the bacterial membranes with an external needle and needle tip complex that senses target cell contact. The proteins make up the T3SA are highly conserved among closely related bacteria making them the ideal serotype-independent candidates for broadly protective vaccines. We have developed a subunit vaccine by fusing the Shigella T3SA proteins. We have shown it is protective in mice and non-human primates using a variety of routes and adjuvants. Currently, we are using this same platform to develop a broadly protective vaccine against Salmonella.
Distinguished Professor Picking earned his Ph.D. at the University of Kansas. He is the director of the Kansas Vaccine Development Center and director of the Higuchi Biosciences Center.
Professor Schöneich is the Takeru Higuchi Distinguished Professor and Chair of the Department of Pharmaceutical Chemistry. He earned his diplom in 1987 from the Free University Berlin (Germany) and his Ph.D. in 1990 at the Technical University Berlin (Germany).
Professor Teruna Siahaan earned a B.S. and an M.S. from the University of Indonesia and a Ph.D. from the University of Arizona. He completed a postdoctoral fellowship at the University of California, Santa Barbara.
Associate Dean John Stobaugh earned a B.S. from the University of Oklahoma in 1974, an M.S. from the University of Oklahoma in 1977, and a Ph.D. from the University of Kansas in 1982.
Associate Professor Thomas Tolbert earned a B.S. in chemistry from Purdue University, a Ph.D. in Biochemistry from the Massachusetts institute of Technology and completed his postdoctoral research at the Scripps Research Institute.
Distinguished Professor David Volkin earned a BA in chemistry at the University of California, San Diego and a PhD in Biochemical Engineering at the Massachusetts Institute of Technology in Cambridge, Massachusetts.
Prof. Michael Zhuo Wang completed his PhD in 2003 from Duke University (Durham, North Carolina, USA) and postdoctoral studies from University of North Carolina at Chapel Hill, School of Pharmacy (Chapel Hill, North Carolina, USA). Dr. Wang received his BS in Chemistry in 1998 from Peking University (Beijing, China). He is now an Associate Professor and Assistant Director of Graduate Studies in the Department of Pharmaceutical Chemistry, University of Kansas (Lawrence, Kansas, USA). He has published more than 30 peer-reviewed papers in reputed journals in the fields of analytical chemistry, pharmacology and pharmaceutics, and has served as an Editorial Board Member for several journals.